Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Wegovy® to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and…